Management of Heterozygous MTHFR Mutations

Assessment and Diagnosis

Individuals with heterozygous MTHFR mutations may have elevated homocysteine levels, particularly when nutritional folate status is marginal 2, 3
Confirm elevated homocysteine with repeat testing after at least 8 hours of fasting 2
The threshold for diagnosis of hyperhomocysteinemia is typically 15 μM, though values between 10-15 μM may confer a graded risk 3
Measure serum and erythrocyte folate, serum cobalamin (B12), and serum and/or urine methylmalonic acid levels to determine the basis of elevated homocysteine 3

Riboflavin (vitamin B2) supplementation at 1.6 mg/day is recommended for individuals with MTHFR mutations to normalize homocysteine levels 1
For patients with hypertension and the MTHFR 677 TT genotype, targeted riboflavin supplementation (1.6 mg/day) has been shown to lower systolic blood pressure, independently of antihypertensive medications 1
Folate and B vitamins should be administered to individuals with MTHFR mutations to normalize homocysteine levels 4

The American Heart Association recommends treatment with vitamin B12 (0.02-1 mg/day), folic acid (0.4-5 mg/day), and vitamin B6 (50-250 mg/day) 5

Monitor response to therapy through clinical improvement, normalization of blood counts, and reduction in homocysteine levels 5
The efficacy of therapy can be monitored by measurement of total homocysteine and, if cobalamin deficiency is present, of urine or blood methylmalonic acid 3

Female family members who are pregnant or considering oral contraceptive use should be screened for both genetic and non-genetic prothrombotic risk factors 6
The American College of Obstetricians and Gynecologists suggests screening pregnant women with a family history of thrombosis 6
Carriers of factor V Leiden mutation may be at higher risk for thrombosis when using oral contraceptives 6

Never treat with folic acid alone if vitamin B12 deficiency has not been ruled out, as this can mask hematologic manifestations while allowing neurological damage to progress 5, 3
When using B12 supplements, methylcobalamin or hydroxycobalamin should be preferred over cyanocobalamin, especially in patients with renal dysfunction 5

B vitamins have been shown to reduce ischemic stroke by 43% in patients with elevated homocysteine 5